Načítá se...
LYN-activating mutations mediate antiestrogen resistance in estrogen receptor–positive breast cancer
Estrogen receptor–positive (ER(+)) breast cancers adapt to hormone deprivation and become resistant to antiestrogen therapy. Here, we performed deep sequencing on ER(+) tumors that remained highly proliferative after treatment with the aromatase inhibitor letrozole and identified a D189Y mutation in...
Uloženo v:
| Vydáno v: | J Clin Invest |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society for Clinical Investigation
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4348968/ https://ncbi.nlm.nih.gov/pubmed/25401474 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI72573 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|